





**CORRECTION**



# Correction to: Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model

Christina Gross , Anwesha Banerjee, Durgesh Tiwari, Francesco Longo , Angela R. White, A. G. Allen, Lindsay M. Schroeder-Carter, Joseph C. Krzeski, Nada A. Elsayed, Rosemary Puckett, Eric Klann, Ralph A. Rivero, Shannon L. Gourley and Gary J. Bassell

© The Author(s), under exclusive licence to American College of Neuropsychopharmacology 2022

*Neuropsychopharmacology* (2022) 47:1733; <https://doi.org/10.1038/s41386-022-01345-x>

Correction to: *Neuropsychopharmacology* <https://doi.org/10.1038/s41386-018-0150-5>, published online 13 July 2018

In this article, Dr. Gary J. Bassell ([gary.bassell@emory.edu](mailto:gary.bassell@emory.edu)) has been added as corresponding author in the web version of this article. The original article has been corrected.